Selexis, Inotrem Partner to Advance Inotrem’s Inflammatory Disease Program

p.p1 {margin: 0.0px 0.0px 8.0px 0.0px; font: 11.0px ‘Trebuchet MS’} p.p2 {margin: 0.0px 0.0px 8.0px 0.0px; font: 11.0px ‘Trebuchet MS’; min-height: 12.0px} span.s1 {letter-spacing: 0.0px}

Selexis SA, a JSR Life Sciences company, and Inotrem SA, a clinical-stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, have signed a service agreement to develop the cell line for Inotrem’s antibody-based candidate to address chronic inflammations. Inotrem will leverage Selexis’ SUREtechnology Platform, a suite of cell line development technologies designed to significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines.

“The Selexis SUREtechnology Platform has demonstrated value in advancing cell lines for many inflammatory disease therapeutics. In turn, the Selexis team has helped our partners all over the world advance their programs from preclinical development to commercialization,” said Sonja Delalu, PhD, Selexis associate director, business development and licensing. “Research around the TREM-1 pathway is promising, and Inotrem’s approach to targeting inflammatory diseases is novel and exciting. We look forward to providing the Inotrem team with a robust research cell bank.”

TREM-1 (triggering receptor expressed on myeloid cells-1) is an immunoreceptor expressed on innate immune cells. Inotrem is focused on the biology of TREM-1 pathway, an innate immune amplifier, to control innate immunity and restore a balanced response in inflammatory diseases.

“With multiple complex factors to consider, selecting a cell line development partner is an incredibly daunting task. Selexis’ reputation for delivering a robust, flexible protein expression platform made our decision a simple one,” said Marc Derive, Inotrem’s chief scientific officer and co-founder. “From their expert team to their SUREtechnology Platform, Selexis checks all of the boxes for a successful partnership. We are looking forward to working with them during this pivotal time in the development of our new asset that addresses chronic inflammatory conditions.”